Early Neurological Outcome of Young Infants Exposed to Selective Serotonin Reuptake Inhibitors during Pregnancy: Results from the Observational SMOK Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  de Vries, Nathalie K S ^a   van der Veere, Christine N ^b   Reijneveld, Sijmen A ^c   Bos, Arend F ^d  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; BODY MOVEMENT; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MATERNAL WELFARE; MOTOR OPTIMALITY SCORE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR PERFORMANCE; PUERPERAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SIDE EFFECT; STATE TRAIT ANXIETY INVENTORY; THIRD TRIMESTER PREGNANCY; ANXIETY; DEPRESSION; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; MALE; MOTOR ACTIVITY; PREGNANCY; PRENATAL EXPOSURE; RISK; YOUNG ADULT;

BRYOPHYTA;

ADULT; ANXIETY; DEPRESSION; FEMALE; HUMANS; INFANT; MALE; MATERNAL EXPOSURE; MOTOR ACTIVITY; ODDS RATIO; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84878415206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064654     Document Type: Article

References (34)

1. Field T, Diego M, Hernandez-Reif M, (2006) Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 29: 445-55.
2. Martini J, Knappe S, Beesdo-Baum K, Lieb R, Wittchen HU, (2010) Anxiety disorders before birth and self-perceived distress during pregnancy: associations with maternal depression and obstetric, neonatal and early childhood outcomes. Early Hum Dev 86: 305-10.
3. Talge NM, Neal C, Glover V, (2007) Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry 48: 245-61.
4. Veere V, Bos AF, (2007) [Use of SSRIs during pregnancy and possible consequences for the development of the child]. Ned Tijdschr Geneeskd 151: 2873-4.
5. Stewart DE, (2011) Clinical practice. Depression during Pregnancy. N Engl J Med 365: 1605-11.
6. Andersson L, Sundstrom-Poromaa I, Bixo M, Wulff M, Bondestam K, et al. (2003) Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 189: 148-54.
7. Meades R, Ayers S, (2011) Anxiety measures validated in perinatal populations: A systematic review. J Affect Disord 133: 1-15.
8. Cooper WO, Willy ME, Pont SJ, Ray WA, (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196: 544-5.
9. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg, et al. (2006) Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62: 863-70.
10. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, et al. (2009) Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42: 95-100.
11. Field T, Diego M, Hernandez-Reif M, (2010) Prenatal depression effects and interventions: A review. Infant Behav Dev 33: 409-18.
12. Gentile S, (2009) Prolonged exposure to SRIs during pregnancy increases risks of adverse neonatal outcomes. Evid Based Ment Health 12: 27.
13. Gentile S, Galbally M, (2010) Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review. J Affect Disord 128: 1-9.
14. Gentile S, (2010) On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 15: 167-85.
15. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR Jr, Vazquez DM, (2005) Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 25: 595-604.
16. Ververs TF, van Wensen K, Freund MW, van der Heide M, Visser GH, et al. (2009) Association between antidepressant drug use during pregnancy and child healthcare utilisation. BJOG 116: 1568-77.
17. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, et al. (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 10: 51-61.
18. Montgomery SA (2008) Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr (Suppl 11): 27-33.
19. Vittinghoff E, McCulloch CE, (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710-8.
20. WHO Collaborating Centre for Drug Statistics Methodology. Available: http://www.whocc.no/atc_ddd_index/Accessed 2013 April 20.
21. Einspieler C, Prechtl HF, (2005) Prechtl's assessment of general movements: a diagnostic tool for the functional assessment of the young nervous system. Ment Retard Dev Disabil Res Rev 11: 61-7.
22. Prechtl HFR, (1974) The behavioural state of the newborn (a review). Brain Res 76: 185-212.
23. Bruggink JL, Einspieler C, Butcher PR, Van Braeckel KN, Prechtl HF, et al. (2008) The quality of the early motor repertoire in preterm infants predicts minor neurologic dysfunction at school age. J Pediatr 153: 32-9.
24. de Vries NK, Bos AF, (2010) The quality of general movements in the first ten days of life in preterm infants. Early Hum Dev 86: 225-9.
25. Prechtl HF, (1980) The optimality concept. Early Hum Dev 4: 201-5.
26. Bruggink JL, Einspieler C, Butcher PR, Stremmelaar EF, Prechtl HF, et al. (2009) Quantitative aspects of the early motor repertoire in preterm infants: do they predict minor neurological dysfunction at school age? Early Hum Dev 85: 25-36.
27. Lasa L, Ayuso-Mateos JL, Vazquez-Barquero JL, Diez-Manrique FJ, Dowrick CF, (2000) The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis. J Affect Disord 57: 261-5.
28. Costei AM, Kozer E, Ho T, Ito S, Koren G, (2002) Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 156: 1129-32.
29. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W, (2004) Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65: 230-7.
30. Zeskind PS, Stephens LE, (2004) Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113: 368-75.
31. Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, et al. (2011) Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 28: 1008-19.
32. Mulder EJ, Ververs FF, de HR, Visser GH (2011) Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus. Neuropsychopharmacology doi:10.1038/npp.2011.67.
33. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, et al. (2005) Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293: 2372-83.
34. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, et al. (2005) Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115: 411-25.